Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients

Joannes F.M. Jacobs; Erik H.J.G. Aarntzen; Lenny A.G. Sibelt; Willeke A. Blokx; Anna C.I. Boullart; Marie Jeanne Gerritsen; Peter M. Hoogerbrugge; Carl G. Figdor; Gosse J. Adema; Cornelis J.A. Punt; I. Jolanda M. De Vries

doi:10.1007/s00262-008-0506-5

Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients

Joannes F.M. Jacobs, Erik H.J.G. Aarntzen, Lenny A.G. Sibelt, Willeke A. Blokx, Anna C.I. Boullart, Marie Jeanne Gerritsen, Peter M. Hoogerbrugge, Carl G. Figdor, Gosse J. Adema, Cornelis J.A. Punt, I. Jolanda M. De Vries

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

The occurrence of vitiligo in patients with melanoma is especially reported for patients undergoing immunotherapy. While vitiligo in these patients is thought to be related to an immune response directed against melanoma cells, solid evidence is lacking. Here we report local cytotoxic T cell reactivity in three melanoma patients who developed vitiligo, after experimental immunotherapy using dendritic cell vaccinations. Tetramer analysis showed that vaccine-induced T cells recognizing gp100 and tyrosinase are present at the vitiligo lesions. These T cells secrete IFN-γ and IL-2 upon peptide specific stimulation as well as upon recognition of the autologous tumor. We show that functional CD8⁺ T cells specific for melanoma differentiation antigens used in a melanoma immunotherapy trial, do not only invade the tumor, but also the vitiligo lesions. This directly links vitiligo to the immuno-therapeutic intervention and supports the hypothesis that vitiligo is a marker of immunity against melanoma cells.

Original language	English
Pages (from-to)	145-151
Number of pages	7
Journal	Cancer Immunology, Immunotherapy
Volume	58
Issue number	1
DOIs	https://doi.org/10.1007/s00262-008-0506-5
Publication status	Published - Jan 2009
Externally published	Yes

Keywords

Melanoma
Melanoma differentiation antigen
T cells
Vitiligo

Access to Document

10.1007/s00262-008-0506-5

Cite this

Jacobs, J. F. M., Aarntzen, E. H. J. G., Sibelt, L. A. G., Blokx, W. A., Boullart, A. C. I., Gerritsen, M. J., Hoogerbrugge, P. M., Figdor, C. G., Adema, G. J., Punt, C. J. A., & De Vries, I. J. M. (2009). Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunology, Immunotherapy, 58(1), 145-151. https://doi.org/10.1007/s00262-008-0506-5

@article{f0e81dd250e345ee8ae80164ba819880,

title = "Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients",

abstract = "The occurrence of vitiligo in patients with melanoma is especially reported for patients undergoing immunotherapy. While vitiligo in these patients is thought to be related to an immune response directed against melanoma cells, solid evidence is lacking. Here we report local cytotoxic T cell reactivity in three melanoma patients who developed vitiligo, after experimental immunotherapy using dendritic cell vaccinations. Tetramer analysis showed that vaccine-induced T cells recognizing gp100 and tyrosinase are present at the vitiligo lesions. These T cells secrete IFN-γ and IL-2 upon peptide specific stimulation as well as upon recognition of the autologous tumor. We show that functional CD8+ T cells specific for melanoma differentiation antigens used in a melanoma immunotherapy trial, do not only invade the tumor, but also the vitiligo lesions. This directly links vitiligo to the immuno-therapeutic intervention and supports the hypothesis that vitiligo is a marker of immunity against melanoma cells.",

keywords = "Melanoma, Melanoma differentiation antigen, T cells, Vitiligo",

author = "Jacobs, {Joannes F.M.} and Aarntzen, {Erik H.J.G.} and Sibelt, {Lenny A.G.} and Blokx, {Willeke A.} and Boullart, {Anna C.I.} and Gerritsen, {Marie Jeanne} and Hoogerbrugge, {Peter M.} and Figdor, {Carl G.} and Adema, {Gosse J.} and Punt, {Cornelis J.A.} and {De Vries}, {I. Jolanda M.}",

note = "Funding Information: Acknowledgments This study was supported by grants KUN 1999/ 1950, 2000/2301, 2003/2893, 2003/2917 and 2006/3699 from the Dutch Cancer Society and the TIL-foundation.",

year = "2009",

month = jan,

doi = "10.1007/s00262-008-0506-5",

language = "English",

volume = "58",

pages = "145--151",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients

AU - Jacobs, Joannes F.M.

AU - Aarntzen, Erik H.J.G.

AU - Sibelt, Lenny A.G.

AU - Blokx, Willeke A.

AU - Boullart, Anna C.I.

AU - Gerritsen, Marie Jeanne

AU - Hoogerbrugge, Peter M.

AU - Figdor, Carl G.

AU - Adema, Gosse J.

AU - Punt, Cornelis J.A.

AU - De Vries, I. Jolanda M.

N1 - Funding Information: Acknowledgments This study was supported by grants KUN 1999/ 1950, 2000/2301, 2003/2893, 2003/2917 and 2006/3699 from the Dutch Cancer Society and the TIL-foundation.

PY - 2009/1

Y1 - 2009/1

N2 - The occurrence of vitiligo in patients with melanoma is especially reported for patients undergoing immunotherapy. While vitiligo in these patients is thought to be related to an immune response directed against melanoma cells, solid evidence is lacking. Here we report local cytotoxic T cell reactivity in three melanoma patients who developed vitiligo, after experimental immunotherapy using dendritic cell vaccinations. Tetramer analysis showed that vaccine-induced T cells recognizing gp100 and tyrosinase are present at the vitiligo lesions. These T cells secrete IFN-γ and IL-2 upon peptide specific stimulation as well as upon recognition of the autologous tumor. We show that functional CD8+ T cells specific for melanoma differentiation antigens used in a melanoma immunotherapy trial, do not only invade the tumor, but also the vitiligo lesions. This directly links vitiligo to the immuno-therapeutic intervention and supports the hypothesis that vitiligo is a marker of immunity against melanoma cells.

AB - The occurrence of vitiligo in patients with melanoma is especially reported for patients undergoing immunotherapy. While vitiligo in these patients is thought to be related to an immune response directed against melanoma cells, solid evidence is lacking. Here we report local cytotoxic T cell reactivity in three melanoma patients who developed vitiligo, after experimental immunotherapy using dendritic cell vaccinations. Tetramer analysis showed that vaccine-induced T cells recognizing gp100 and tyrosinase are present at the vitiligo lesions. These T cells secrete IFN-γ and IL-2 upon peptide specific stimulation as well as upon recognition of the autologous tumor. We show that functional CD8+ T cells specific for melanoma differentiation antigens used in a melanoma immunotherapy trial, do not only invade the tumor, but also the vitiligo lesions. This directly links vitiligo to the immuno-therapeutic intervention and supports the hypothesis that vitiligo is a marker of immunity against melanoma cells.

KW - Melanoma

KW - Melanoma differentiation antigen

KW - T cells

KW - Vitiligo

UR - http://www.scopus.com/inward/record.url?scp=54849412580&partnerID=8YFLogxK

U2 - 10.1007/s00262-008-0506-5

DO - 10.1007/s00262-008-0506-5

M3 - Article

C2 - 18392619

AN - SCOPUS:54849412580

SN - 0340-7004

VL - 58

SP - 145

EP - 151

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 1

ER -

Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this